FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2156661254> ?p ?o ?g. }

• W2156661254 endingPage "44" @default.
• W2156661254 startingPage "37" @default.
• W2156661254 abstract "To compare the efficacy and safety of chondroitin sulfate plus glucosamine hydrochloride (CS+GH) versus celecoxib in patients with knee osteoarthritis and severe pain.Double-blind Multicentre Osteoarthritis interVEntion trial with SYSADOA (MOVES) conducted in France, Germany, Poland and Spain evaluating treatment with CS+GH versus celecoxib in 606 patients with Kellgren and Lawrence grades 2-3 knee osteoarthritis and moderate-to-severe pain (Western Ontario and McMaster osteoarthritis index (WOMAC) score ≥301; 0-500 scale). Patients were randomised to receive 400 mg CS plus 500 mg GH three times a day or 200 mg celecoxib every day for 6 months. The primary outcome was the mean decrease in WOMAC pain from baseline to 6 months. Secondary outcomes included WOMAC function and stiffness, visual analogue scale for pain, presence of joint swelling/effusion, rescue medication consumption, Outcome Measures in Rheumatology Clinical Trials and Osteoarthritis Research Society International (OMERACT-OARSI) criteria and EuroQoL-5D.The adjusted mean change (95% CI) in WOMAC pain was -185.7 (-200.3 to -171.1) (50.1% decrease) with CS+GH and -186.8 (-201.7 to -171.9) (50.2% decrease) with celecoxib, meeting the non-inferiority margin of -40: -1.11 (-22.0 to 19.8; p=0.92). All sensitivity analyses were consistent with that result. At 6 months, 79.7% of patients in the combination group and 79.2% in the celecoxib group fulfilled OMERACT-OARSI criteria. Both groups elicited a reduction >50% in the presence of joint swelling; a similar reduction was seen for effusion. No differences were observed for the other secondary outcomes. Adverse events were low and similarly distributed between groups.CS+GH has comparable efficacy to celecoxib in reducing pain, stiffness, functional limitation and joint swelling/effusion after 6 months in patients with painful knee osteoarthritis, with a good safety profile.NCT01425853." @default.
• W2156661254 created "2016-06-24" @default.
• W2156661254 creator A5000242035 @default.
• W2156661254 creator A5004498996 @default.
• W2156661254 creator A5006145931 @default.
• W2156661254 creator A5012454701 @default.
• W2156661254 creator A5013562795 @default.
• W2156661254 creator A5013654725 @default.
• W2156661254 creator A5019811024 @default.
• W2156661254 creator A5026165132 @default.
• W2156661254 creator A5026582019 @default.
• W2156661254 creator A5026711692 @default.
• W2156661254 creator A5042828595 @default.
• W2156661254 creator A5049564443 @default.
• W2156661254 creator A5083600483 @default.
• W2156661254 creator A5084376077 @default.
• W2156661254 creator A5085771274 @default.
• W2156661254 creator A5086784431 @default.
• W2156661254 date "2015-01-14" @default.
• W2156661254 modified "2023-10-17" @default.
• W2156661254 title "Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib" @default.
• W2156661254 cites W1599185368 @default.
• W2156661254 cites W1926898034 @default.
• W2156661254 cites W1967927251 @default.
• W2156661254 cites W1973371445 @default.
• W2156661254 cites W1980120754 @default.
• W2156661254 cites W1981816788 @default.
• W2156661254 cites W1983104516 @default.
• W2156661254 cites W1983111989 @default.
• W2156661254 cites W2008797359 @default.
• W2156661254 cites W2017304854 @default.
• W2156661254 cites W2057647525 @default.
• W2156661254 cites W2074339153 @default.
• W2156661254 cites W2097950056 @default.
• W2156661254 cites W2101211236 @default.
• W2156661254 cites W2103405837 @default.
• W2156661254 cites W2107949345 @default.
• W2156661254 cites W2115805053 @default.
• W2156661254 cites W2117896603 @default.
• W2156661254 cites W2120551915 @default.
• W2156661254 cites W2121319738 @default.
• W2156661254 cites W2124790232 @default.
• W2156661254 cites W2130513475 @default.
• W2156661254 cites W2146638509 @default.
• W2156661254 cites W2149486484 @default.
• W2156661254 cites W2153862724 @default.
• W2156661254 cites W2156028141 @default.
• W2156661254 cites W2158093746 @default.
• W2156661254 cites W2161097107 @default.
• W2156661254 cites W2161739351 @default.
• W2156661254 cites W2164036238 @default.
• W2156661254 cites W2164402473 @default.
• W2156661254 cites W2186657631 @default.
• W2156661254 cites W2197016826 @default.
• W2156661254 cites W49380918 @default.
• W2156661254 doi "https://doi.org/10.1136/annrheumdis-2014-206792" @default.
• W2156661254 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4717399" @default.
• W2156661254 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25589511" @default.
• W2156661254 hasPublicationYear "2015" @default.
• W2156661254 type Work @default.
• W2156661254 sameAs 2156661254 @default.
• W2156661254 citedByCount "186" @default.
• W2156661254 countsByYear W21566612542015 @default.
• W2156661254 countsByYear W21566612542016 @default.
• W2156661254 countsByYear W21566612542017 @default.
• W2156661254 countsByYear W21566612542018 @default.
• W2156661254 countsByYear W21566612542019 @default.
• W2156661254 countsByYear W21566612542020 @default.
• W2156661254 countsByYear W21566612542021 @default.
• W2156661254 countsByYear W21566612542022 @default.
• W2156661254 countsByYear W21566612542023 @default.
• W2156661254 crossrefType "journal-article" @default.
• W2156661254 hasAuthorship W2156661254A5000242035 @default.
• W2156661254 hasAuthorship W2156661254A5004498996 @default.
• W2156661254 hasAuthorship W2156661254A5006145931 @default.
• W2156661254 hasAuthorship W2156661254A5012454701 @default.
• W2156661254 hasAuthorship W2156661254A5013562795 @default.
• W2156661254 hasAuthorship W2156661254A5013654725 @default.
• W2156661254 hasAuthorship W2156661254A5019811024 @default.
• W2156661254 hasAuthorship W2156661254A5026165132 @default.
• W2156661254 hasAuthorship W2156661254A5026582019 @default.
• W2156661254 hasAuthorship W2156661254A5026711692 @default.
• W2156661254 hasAuthorship W2156661254A5042828595 @default.
• W2156661254 hasAuthorship W2156661254A5049564443 @default.
• W2156661254 hasAuthorship W2156661254A5083600483 @default.
• W2156661254 hasAuthorship W2156661254A5084376077 @default.
• W2156661254 hasAuthorship W2156661254A5085771274 @default.
• W2156661254 hasAuthorship W2156661254A5086784431 @default.
• W2156661254 hasBestOaLocation W21566612541 @default.
• W2156661254 hasConcept C105702510 @default.
• W2156661254 hasConcept C126322002 @default.
• W2156661254 hasConcept C14184104 @default.
• W2156661254 hasConcept C142724271 @default.
• W2156661254 hasConcept C153074725 @default.
• W2156661254 hasConcept C168563851 @default.
• W2156661254 hasConcept C1862650 @default.
• W2156661254 hasConcept C204787440 @default.
• W2156661254 hasConcept C2776164576 @default.

• next